Immunome (IMNM) Cash from Investing Activities (2019 - 2026)

Immunome has reported Cash from Investing Activities for 8 years, with the latest figure at -$12.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 336.12% year-over-year to -$12.0 million; the trailing twelve-month figure through Mar 2026 stood at $43.7 million (up 202.23% YoY), and the FY2025 full-year result was $60.8 million, up 171.48% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$12.0 million, down from -$4.0 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $123.9 million in Q3 2025, with the low at -$81.7 million in Q2 2024.
• Historically, Cash from Investing Activities has averaged -$4.2 million across 5 years, with a median of -$138000.0 in 2022.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities plunged 41569.44% — and 2024, when it surged 67038.89%.
• Immunome's Cash from Investing Activities stood at -$72000.0 in 2022, then sank by 41569.44% to -$30.0 million in 2023, then jumped by 132.52% to $9.8 million in 2024, then sank by 140.98% to -$4.0 million in 2025, then plunged by 200.48% to -$12.0 million in 2026.
• The last three Cash from Investing Activities figures came in at -$12.0 million (Q1 2026), -$4.0 million (Q4 2025), and $123.9 million (Q3 2025), per Business Quant data.